Golden Deeps Ltd (ASX:GED) has announced assay results received from diamond drillholes HVD001 and HVD003 at the 100% owned Havilah Project in the Lachlan Fold Belt copper-gold province of central NSW have produced substantial intersections of copper and zinc bearing sulphide mineralisation which also contain zones with significant silver and gold assays

⚒️ Assay results indicate the mineralisation at Havilah is in close proximity to a large porphyry-sulphide system
🪨 Diamond drillhole HVD003, which tested the extensive Hazelbrook copper soil and rockchip anomaly intersected an 84m zone of semi-massive patches, veins and disseminations of chalcopyrite, sphalerite
and pyrite
⛏️ Diamond drillhole HVD001, which tested the Hazelbrook North copper-zinc-gold anomaly intersected 40m of siliceous breccia veining with disseminated sulphide mineralisation from surface, hosted by Silurian volcanic rocks, producing the following significant copper, zinc and silver intersections:

“The assay results for diamond drillholes HVD001 and HVD003 at the Hazelbrook prospect at Havilah have confirmed the discovery of extensive copper-zinc bearing sulphide mineralisation as well as zones of silver and gold mineralisation in the world-class Lachlan Fold Belt in NSW." Golden Deeps CEO Jon Dugdale

Read the ASX announcement ⚡ https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02865119-6A1230548&v=fc9bdb61fe50ea61f8225e24ce041a0e155a9400

3D metal printing and additive manufacturing business Titomic (ASX:TTT) has introduced a groundbreaking augmented reality enhancement for its handheld D523 cold spray system that helps clients in the aerospace, defence and oil and gas industries repair metal components without the use of heat.

⚙️ Adds competitive edge to Titomic’s patented Kinetic Fusion cold spray technology which coats surfaces with strong layers of specialty metals without melting them
🧲Head-worn transparent lens that can display real-time system data for specific repairs such as temperature, system settings, and optimal nozzle range
🔧Enables standardisation of repairs by providing pre-set parameters for tasks such as wheel and landing gear repairs and corrosion mitigation
⚒️Expected to increase industry interest and demand by improving precision, efficiency and repeatability in maintenance and repair operations

ASX announcement ⚡ https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02864268-3A652649&v=fc9bdb61fe50ea61f8225e24ce041a0e155a9400

Mexican inspired casual and fast-food restaurant business Guzman Y Gomez (ASX: GYG) has kept the momentum rolling since listing on the ASX in June this year by delivering $279 million in network sales during the first quarter of FY25, up 20.7 per cent from the same time last year.
🌮 Comparable sales in Australia above expectations on the back of strong delivery performance, successful execution of ‘Clean is the New Healthy’ campaign and demand for value menu items
🌶️ The US segment performed in line with expectations
🌯 Total number of corporate and franchised restaurants across Australia, Singapore, Japan and the US reached 226 during the quarter, up from 204 a year ago
🥑 On track to meet prospectus forecasts for FY25 with 31 new restaurants in Australia projected to open

ASX announcement ⚡ https://announcements.asx.com.au/asxpdf/20241010/pdf/068yfmgpj5qdyl.pdf

Ahead of appearing at the Stocks On Track event, Optiscan Imaging Ltd (ASX:OIL) CEO & Managing Director Dr Camile Farah, speaks with The Stock Network's Lel Smits GAICD and highlights:

🏆 FY24 Strategy milestones
⚙️ Operational and addressable markets focus
🖥️ FY25 outlook

Watch the full interview ⚡ https://youtu.be/CFeQRL53c1g

Shares in Optiscan Imaging (ASX:OIL) have surged more than 170 per cent over the last year as the commercial stage medical technology company advances its suite of digital pathology and precision surgery hardware and software solutions. Optiscan is focused on the development, manufacturing, and commercialisation of imaging technologies for medical, translational and pre-clinical applications. Ahead of appearing at the Stocks On Track event in Melbourne, Optiscan Imaging’s CEO and Managing Director, Dr Camile Farah speaks with The Stock Network's Lel Smits.

1 FY24 Strategy milestones
Optiscan realised a host of development strategy milestones during its 2024 financial year (FY24). What were the biggest milestones achieved over this 12-month period and what makes them so significant?

2 Operational and addressable markets focus
What is Optiscan’s current focus from both an operational and addressable markets perspective and what are the key catalysts for the year ahead?

3 FY25 outlook
How would you like to see the company positioned in a year from now?


_ _ _

Subscribe to TSN's YouTube channel for the latest stock content: https://www.youtube.com/channel/UCEEVNCMFSRxFa0Bb2wKLS0g?sub_confirmation=1
_ _ _

Follow TSN for the latest stock news and interviews:
Twitter: https://twitter.com/thestocknet
Instagram: https://www.instagram.com/thestocknetwork/
LinkedIn: https://www.linkedin.com/company/the-stock-network/
TikTok: https://www.tiktok.com/@thestocknet?lang=en
Facebook: https://www.facebook.com/TheStockNet/

_ _ _
Connect with our host Lel Smits online - @LelSmits
- Twitter / X: https://twitter.com/lelsmits
- Instagram: https://www.instagram.com/lelsmits/
- LinkedIn: https://www.linkedin.com/in/leldesmits/
- TikTok: https://www.tiktok.com/@lelsmits?lang=en
- Facebook: https://m.facebook.com/lelsmits/
- Threads: https://www.threads.net/@lelsmits
_ _ _

Disclaimer
The material contained in this post is general in nature only and does not constitute personal financial or legal advice. None of our material should be regarded as advice and you should not rely on any of the content of this post without first obtaining specific professional advice. We give no warranty to the accuracy, reliability or completeness of information that is contained in this post and exclude liability for any loss.

This post may contain views and opinions which are those of the authors and do not necessarily reflect the official policy or position of any other author, agency, organisation, employer or company. We are not liable for any comment published by users and reserve the right to delete any comment for any reason whatsoever. We have commercial relationships with some of our contributors, and we may receive payment or other benefits from this post. Please see The Stock Network website for our full content disclaimer.

_ _ _

Visit TSN's website to sign up for regular stock updates: www.thestocknetwork.com.au
_ _ _

Counter-drone defense business DroneShield (ASX:DRO) has nailed down a repeat $13.5 million order from a US Government customer for its dismounted C-UxS systems used to protect clients from hostile drone attacks.

🛰️ Full delivery and cash receipt from the new order expected in current quarter
🛡️ DroneShield is the only publicly listed company with pure-play exposure to the rapidly growing counter-drone/counter-UAS sector playing a key role in military, intelligence and law enforcement industries
🚀 New contract builds on a recently reported first-half record in revenue of $24.1 million and cash receipts of $21.4 million for H1FY24

“DroneShield’s ability to rapidly deliver high-performance, lifesaving technology at this scale sets us apart in the counter-UAS industry, empowering our clients with cutting-edge solutions precisely when they need it.” - Tom Branstetter, DroneShield’s Director of Business Development

ASX announcement ⚡https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02863551-2A1554233&v=fc9bdb61fe50ea61f8225e24ce041a0e155a9400

Ahead of appearing at the Stocks On Track event, PolyNovo (ASX:PNV) Non-Executive Chairman David Williams speaks with The Stock Network's Lel Smits and highlights:

⚙️ Unique technology
🏆 Competitive landscape
🤝 Collaborations & innovation
🖋️ Valuation

Watch the full interview ⚡ https://youtu.be/VnjHGpzjBFc

Shares in PolyNovo (ASX:PNV) are up more than 100% over the last year on the back of the development and commercialisation of the Company’s innovative medical devices using its patented NovoSorb technology. PolyNovo medical devices are used for a number of medical applications and the Company has this year achieved record revenues of the back of sales in the US, Europe, Australia, New Zealand, Asia and the Middle East. Ahead of appearing at the Stocks on Track event in Melbourne, PolyNovo Non-executive Chairman David Williams speaks to Lel Smits on The Stock Network.

1 Unique technology
PolyNovo’s flagship product is a special material called NovoSorb, like a plastic that can safely break down in the body over time, and helps to heal wounds better. Why do you think the industry has embraced this technology

2 Competitive landscape
What’s to stop others trending on your toes in this space?

3 Partnerships, collaborations and innovation
The success of medical technologies often involves strategic partnerships. Can you highlight any key collaborations that have been crucial to PolyNovo’s growth, and are there plans for new partnerships or innovation programs in the near future?

4 Valuation
A share price surge of more than 100% over the last year and has had some ask if you’re overvalued. What is PolyNovo’s strategy to maintain and grow current global sales momentum and which markets do you see as having the most potential for growth?

Neuren Pharmaceuticals (ASX:NEU) has discussed proposals for the first ever pivotal clinical trial program in Phelan-McDermid syndrome (PMS) with the US Food and Drug Administration.

⚪️There are no medications approved for PMS, which has severe quality of life impacts on those living with it, as well as on parents and siblings
⚪️At the FDA meeting alignment was reached on key aspects of the NNZ-2591 Phase 3 program, with Neuren to submit further information to confirm endpoints for the primary efficacy assessment

“We are pleased with the outcomes of a very collaborative meeting with the FDA and are eager to move forward in our mission to develop NNZ-2591 as a first approved treatment for Phelan-McDermid syndrome, which has an overwhelming unmet need.” - Neuren CEO Jon Pilcher

Read the ASX announcement: https://www.neurenpharma.com/pdf/75dd3940-daf0-4876-9e00-085c0246d0be/NEU-continues-PMS-P3-preparations-after-positive-FDA-meeting.pdf